Global health concerns generate new therapies for home and abroad
September 1st 2009Even before the emergence of the swine flu pandemic, biopharmaceutical companies were investing in vaccines and treatments for lethal diseases that plague much of the world. There is growing recognition that Americans and Europeans are vulnerable to infections from overseas, and that development of new medications is critical to ensuring public health.
Read More
Golimumab: A human anti-TNF-alpha monoclonal antibody for the treatment of autoimmune joint diseases
September 1st 2009Golimumab is a human anti-tumor necrosis factor (TNF)-alpha monoclonal antibody that was recently approved for the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Read More